NASDAQ: VCREVicore Pharma Holding Ab Stock
$15.03-1.22 (-7.51%)
Updated Jul 7, 2026
VCRE Price
$15.03
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$13.55
52 Week High
$17.80
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VCRE Overview
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VCRE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VCRE
Ranked#119 of 462
Ranked#119 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $247.72 | A | |
| $10.34 | A | |
| $16.22 | A |
Be the first to know about important VCRE news, forecast changes, insider trades & much more!
VCRE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VCRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VCRE's short-term assets ($113.32M) exceed its short-term liabilities ($8.93M)
Short-term Liabilities Financials
VCRE's short-term assets ($113.32M) exceed its long-term liabilities ($178.27k)
Long-term Liabilities Financials
VCRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
There are 30 more VCRE due diligence checks available for Premium users.
Valuation
VCRE's financial health
Profit margin
Revenue
$64.4k
Net Income
-$11.6M
Profit Margin
-18,042.5%
Assets to liabilities
Assets
$115.2M
Liabilities
$9.2M
Debt to equity
0.09
VCRE's short-term assets ($113.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VCRE's short-term assets ($113.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VCRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.6M
Investing
-$9.5M
Financing
$0.0
Vicore Pharma Holding Ab Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.